TNFRSF10B and neoplasm: These findings, taken together with TRAIL-R2 differential expression between tumor and normal cells, strongly suggest that this receptor should be considered as a tumor-associated antigen [31,32], and corroborate previous evidence of BsAb anti-neoplastic activity [6].